Alumis (ALMS) Change in Accured Expenses (2023 - 2025)
Alumis (ALMS) posted quarterly Change in Accured Expenses of $3.5 million for Q4 2025, up 11.75% year-over-year from $3.1 million in Q4 2024, and up 187.42% quarter-over-quarter from -$4.0 million in Q3 2025.
Analysis
Alumis (ALMS) Change in Accured Expenses (2023 - 2025) Analysis & Trends
Alumis (ALMS) has reported Change in Accured Expenses for 3 consecutive years, with $3.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses rose 11.75% year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $6.0 million (up 70.41% YoY), while the FY2025 annual figure was $6.0 million, up 70.41% from the prior year.
- Change in Accured Expenses advanced to $3.5 million in Q4 2025 per ALMS's latest filing, from -$4.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $5.0 million in Q1 2025 and bottomed at -$4.0 million in Q3 2025.
- Historically, Change in Accured Expenses has averaged $1.2 million across 3 years, with a median of $1.6 million in 2023.
- On a YoY basis, Change in Accured Expenses climbed as much as 255.29% in 2025 and fell as far as 270.36% in 2025.
- Alumis' Change in Accured Expenses stood at $1.6 million in 2023, then soared by 91.64% to $3.1 million in 2024, then climbed by 11.75% to $3.5 million in 2025.
- Business Quant data shows ALMS's Change in Accured Expenses at $3.5 million in Q4 2025, -$4.0 million in Q3 2025, and $1.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Alumis | 1.42 Bn | 917.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 3.48 Mn |
| Sep 30, 2025 | -3.98 Mn |
| Jun 30, 2025 | 1.55 Mn |
| Mar 31, 2025 | 4.99 Mn |
| Dec 31, 2024 | 3.12 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | -3.21 Mn |
| Dec 31, 2023 | 1.63 Mn |
| Sep 30, 2023 | 1.11 Mn |